Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials

Authors

Institutions

Publication Details

Journal
Clinical Genitourinary Cancer
Published
2024-11-15
DOI
https://doi.org/10.1016/j.clgc.2024.102273
Citations
1
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials

José Ángel Arranz, Abhishek Bavle, Eli Rosenbaum, Sun Young Rha et al.
1 citations
Clinical Genitourinary Cancer
Bladder and Urothelial Cancer Treatments
0.57
article

Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials

José Ángel Arranz, Abhishek Bavle, Eli Rosenbaum, Sun Young Rha, David Sarid, Ying‐Chun Shen, José Muñoz-Langa, Jean‐Pascal Machiels, Naoto Sassa, Bhumsuk Keam, Maureen J.B. Aarts, Blanca Homet Moreno, Yasuhisa Fujii, Patrizia Giannatempo, Stéphane Culine, Jing Xu, Wen-Pin Su, Fabio Calabrò
article en
1 citations

Abstract

No abstract available for this paper.
Clinical Genitourinary CancerVol. 23(2)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Cliniques Universitaires Saint-Luc (BE), Aichi Medical University (JP), Université Paris Cité (FR), Tel Aviv Sourasky Medical Center (IL), Maastricht University Medical Centre (NL), Rabin Medical Center (IL), Seoul National University Hospital (KR), Hospital General Universitario Gregorio Marañón (ES), Hospital Universitari i Politècnic La Fe (ES), Assistance Publique – Hôpitaux de Paris (FR), National Taiwan University Hospital (TW), Hôpital Saint-Louis (FR), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), National Cheng Kung University Hospital (TW), Yonsei University Health System (KR)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Handok, Merck KGaA, Taiho Pharmaceutical, Les Laboratories Pierre Fabre, BeiGene, Incyte, MacroGenics, Seagen, Eisai, Astellas Pharma, Ono Pharmaceutical, Ipsen, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 28%
Bladder and Urothelial Cancer Treatments
0.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.